JP2017507969A - がん幹細胞標的化合物 - Google Patents

がん幹細胞標的化合物 Download PDF

Info

Publication number
JP2017507969A
JP2017507969A JP2016556878A JP2016556878A JP2017507969A JP 2017507969 A JP2017507969 A JP 2017507969A JP 2016556878 A JP2016556878 A JP 2016556878A JP 2016556878 A JP2016556878 A JP 2016556878A JP 2017507969 A JP2017507969 A JP 2017507969A
Authority
JP
Japan
Prior art keywords
group
cancer
cancer stem
compound
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016556878A
Other languages
English (en)
Japanese (ja)
Inventor
サンギータ スリヴァスタヴァ
サンギータ スリヴァスタヴァ
マイティリ アタヴァレ
マイティリ アタヴァレ
ケダール シュクレ
ケダール シュクレ
ガヤトリ モレ
ガヤトリ モレ
Original Assignee
ゴーダーヴァリ バイオリファイナリーズ リミテッド
ゴーダーヴァリ バイオリファイナリーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゴーダーヴァリ バイオリファイナリーズ リミテッド, ゴーダーヴァリ バイオリファイナリーズ リミテッド filed Critical ゴーダーヴァリ バイオリファイナリーズ リミテッド
Publication of JP2017507969A publication Critical patent/JP2017507969A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2016556878A 2014-03-11 2015-03-11 がん幹細胞標的化合物 Pending JP2017507969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN815/MUM/2014 2014-03-11
IN815MU2014 IN2014MU00815A (enExample) 2014-03-11 2015-03-11
PCT/IN2015/050020 WO2015136557A2 (en) 2014-03-11 2015-03-11 Cancer stem cell targeting compounds

Publications (1)

Publication Number Publication Date
JP2017507969A true JP2017507969A (ja) 2017-03-23

Family

ID=54072550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016556878A Pending JP2017507969A (ja) 2014-03-11 2015-03-11 がん幹細胞標的化合物

Country Status (9)

Country Link
US (1) US20180169100A1 (enExample)
EP (1) EP3116867A4 (enExample)
JP (1) JP2017507969A (enExample)
AU (1) AU2015228386A1 (enExample)
CA (1) CA2941703A1 (enExample)
IL (1) IL247723A0 (enExample)
IN (1) IN2014MU00815A (enExample)
MX (1) MX2016011675A (enExample)
WO (1) WO2015136557A2 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021552A1 (en) * 2003-08-29 2005-03-10 Vernalis (Cambridge) Ltd Pyrimidothiophene compounds
GB0416168D0 (en) * 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2473054B1 (en) * 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOGOLUBSKY, A. V. ET AL., J. COMB. CHEM., vol. 9, JPN6018038586, 2007, pages 661 - 667, ISSN: 0003892252 *
TIMKEVICIOUS, S. ET AL., CHEMIJA, vol. 1, JPN6018038585, 1997, pages 58 - 61, ISSN: 0003892251 *

Also Published As

Publication number Publication date
IN2014MU00815A (enExample) 2015-09-25
US20180169100A1 (en) 2018-06-21
EP3116867A4 (en) 2017-10-18
CA2941703A1 (en) 2015-09-17
EP3116867A2 (en) 2017-01-18
IL247723A0 (en) 2016-11-30
WO2015136557A2 (en) 2015-09-17
WO2015136557A3 (en) 2015-11-12
MX2016011675A (es) 2016-12-14
AU2015228386A1 (en) 2016-09-22
WO2015136557A9 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
EP3600270B1 (en) Compounds and compositions for treating hematological disorders
ES3041635T3 (en) Macrocyclic compounds for inhibiting and inducing degradation of egfr kinase in the treatment of cancer
US11396495B2 (en) Amine compound for inhibiting SSAO/VAP-1 and use thereof
DK2364302T3 (en) TRIAZINE ANALOGS AND THE USE THEREOF AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBE
CA3128468A1 (en) P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
EP2588457A1 (de) Pyrazolochinoline
EP1914234A1 (en) Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
CN119744263A (zh) Prmt5抑制剂
US20210269442A1 (en) Fused ring derivative used as fgfr4 inhibitor
WO2023220227A1 (en) Treating diseases and disorders with irak4-modifying compounds
WO2019195789A1 (en) Phenothiazine derivatives and uses thereof
JP2017507969A (ja) がん幹細胞標的化合物
JP2017507163A (ja) がん幹細胞の根絶または増殖阻害のための化合物
TW202409026A (zh) 苯并噻唑化合物及其使用方法
CN114948962A (zh) 二氢嘧啶类化合物在制备抗冠状病毒药物中的用途
HK40013355A (en) Compounds and compositions for treating hematological disorders
HUE031209T2 (hu) Triazin analógok és alkalmazásuk gyógyászati szerként és diagnosztikai próbákként

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190402